{
  "hero": {
    "title": "User Workflow Exploration",
    "subtitle": "Explore the complete user workflow system with detailed AI reasoning explanations",
    "time_investment": "‚è±Ô∏è 15-20 minutes ‚Ä¢ Complete workflow demonstration ‚Ä¢ Multi-stakeholder perspectives"
  },
  "workflow_overview": {
    "title": "Complete User Workflow System",
    "description": "Explore how AdjuvantIQ's ontological AI system supports clinical trial optimization across the entire development lifecycle.",
    "tabs": [
      {
        "id": "adaptive-modifications",
        "title": "Adaptive Modifications",
        "active": true
      },
      {
        "id": "regulatory-strategy", 
        "title": "Regulatory Strategy",
        "active": false
      }
    ]
  },
  "persona": {
    "title": "Study Director - Dr. Jennifer Walsh",
    "context": "Managing ongoing cardiovascular outcomes trial, Month 18 of recruitment",
    "challenge": "Recruitment below target, emerging safety signal requires protocol evaluation"
  },
  "workflow_steps": [
    {
      "step_number": "1",
      "title": "Performance Monitoring Alert",
      "system_analysis": {
        "recruitment": "65% of target enrollment (should be 75% at Month 18)",
        "safety_signal": "Increased UTI reports in treatment arm (15% vs 8% placebo)",
        "geographic_pattern": "Northeastern sites underperforming expectations",
        "competitive_intelligence": "New SGLT2 inhibitor trial launched by competitor"
      }
    },
    {
      "step_number": "2", 
      "title": "Systematic Impact Analysis",
      "system_analysis": {
        "projection_analysis": "Recruitment delay impact on study completion",
        "safety_assessment": "UTI signal clinical significance evaluation",
        "competitive_impact": "Market positioning and enrollment competition"
      }
    }
  ],
  "credibility_indicators": [
    {
      "icon": "üéì",
      "text": "Developed with clinical development leaders and regulatory experts"
    },
    {
      "icon": "üìä",
      "text": "Based on analysis of 50+ adaptive trials and regulatory submission strategies"
    }
  ]
}
